<div id="readability-page-1"><div><p>Sept 25 (Reuters) - Intellia Therapeutics Inc:</p><ul><li>Intellia Therapeutics announces positive longer-term phase 1 data for nexiguran ziclumeran (Nex-Z) in patients with hereditary transthyretin (ATTR) amyloidosis with polyneuropathy</li><li>   Intellia Therapeutics Inc - one dose of Nex-Z shows durable TTR reductions of at least 90% through three years</li><li>   Intellia Therapeutics Inc - favorable safety data with no new drug-related events</li><li>   Intellia Therapeutics Inc - phase 3 Magnitude-2 trial enrollment expected by first half 2026</li></ul></div></div>

Intellia治療

<p>9 月 25 日（路透社）- Intellia Therapeutics Inc：Intellia Therapeutics 宣佈在遺傳性轉甲狀腺素（ATTR）澱粉樣變性伴多發性神經病患者中，nexiguran ziclumeran（Nex-Z）的長期 1 期研究數據積極。Intellia Therapeutics Inc - 一劑 Nex-Z 顯示在三年內 TTR 減少至少 90% 的持久效果。Intellia Therapeutics Inc - 安全性數據良好，沒有新的藥物相關事件。Intellia Therapeutics Inc - 預計在 2026 年上半年開始進行 3 期 Magnitude-2 試驗的招募</p>

Intellia 治療公司稱，Nex-Z 單劑在三年內可持續降低 TTR 至少 90%